NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

NEW YORK CITY, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

The vaccine, manufactured by the biotechnology company Valneva, was the first vaccine approved by the US Food and Drug ...

VALNEVA Declaration of shares and voting rights February 28, 2025_____ Company name: VALNEVARegistered office ...

Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...

Shares of Valneva SE (NASDAQ:VALN – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $6.86, but opened at $7.11. Valneva shares last traded at $ ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – ...

Valneva expects further sales growth this year after it posted higher revenue in 2024. The French vaccine company said Tuesday that it expects total revenue in 2025 to grow to between 180 million ...

More information is available at www.valneva.com. This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business ...

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, “Given the substantial risk that chikungunya presents to individuals residing in or traveling to endemic regions, it's ...